DOCSLIB.ORG

Poisons No. 34 EXPLANATORY NOTE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Poisons No. 34 EXPLANATORY NOTE 130 Poisons No. 34 . (2) Female progeny of the Ministry's bulls used for artificial insemination may be recorded in their first and subsequent lactations free of charge tc· the owner. (3) In the case of the recording, for comparison purposes, of cows not being progeny of the -Ministry's bulls used for ar,tificial inseminaticn only the first lactation shall be recorded free of charge to the owner who, however, on payment of the fee prescribed in Article 8 may have recording of the subsequent lactations sUl?ervised by the Ministry. (4) Where a herd being recorded ceases to use the Ministry's Artificial Insemina­ trcn service or ceases to provide useful information to the Ministry the recording free of charge may be terminated by the Ministry. EXPLANATORY NOTE (This Note is not part of the Scheme but is-intended to indicate its general purport.) This Scheme replaces the previous Scheme and provides for the measure­ ment of milk yields by volumetric as well as gravimetric means. 1964. No. 34 [C] POISONS· ORDER, DATED 28TH FEBRUARY, 1964, MADE BY THE MINisTER OF HOME AFFAiRS UNDER SECTION 26A(6) OF THE MEDICINES, PHARMACY AND POISONS ACT (NORTHERN IRELAND) 1945. Whereas the Poisons Board, constituted in accordance with Section 26 or the Medicines, Pharmacy and Poisons Act (Northern Ireland) 1945(a), has recommended t6 me that the list of substances which are to be treated as poisons for the purposes of the Pharmacy and Poisons Acts (Northern Ireland) 1925 to 1955(b) and known as "the Poisons Schedule" for the purposes of those Acts should be amended so that certain additional substances should be included in Part I of th~ said schedule (which Part consists of those Poisons which, subject to the provisions· of the said Acts, are not to be sold except by a person who js an authorised seller of poisons) and so that a certain other substance should be transferred from Part I to Part II of the said schedule (which Part consists of those Poisons which, subject to the provisions of the said Acts, are not to be sold except by authorised sellers of poisons and those persons who are authorised by the local authority and whose names are entered in a register kept by the local. authority under Seotion .30 of the Act) and so' that there should be certain variations of nomenclature in Part I of the said schedule: . Now, therefore, I, the Right Honourable William Craig, Minister of Home Affairs, in exercise.of the powers conferred on me by Section 26A(6) of the Medicines, Pharmacy and Poisons Act (Northern Ireland) 1945 and ·of all other powers enabling me in that behalf do hereby order as follows: (a) 1945. <;. 9. (b) 15 & 16 Oeo. S.c. 8 anq 1955. c. 31. No. 34 Poisons 131 Citation and Commencement , '1. This Order may be cited as the, Poisons List Order (Northern Ireland) 1964 and shall come into -9peration on 1st April, 1964. Amendments 2. The "Poisons Schedule" for the purposes of the Pharmacy and Poisons Acts (NQrthern Ireland) 1925 to 1955(a) shall be amended and varied as follows, that is to say: (a) Part I shall be amended and varied in the manner specified in the First Schedule; and (b) In Part II after the item "Formic acid" there shall be inserted the item "Hydrofluoric acid"; potassium fluoride, sodium fluoride, sodium silicofluoride; and accordingly the list of substances whioh are to be treated as poisons for the purposes of the Pharmacy and Poisons Acts (Northern Ireland) 1925 to 1955 shall be as set out in the Second Schedule. Dated the 28th day of February. 1964. (Sgd.) Wm. Craig, Minister of Home Affairs for Northern Ireland. FIRST SCHEDULE Amendments and Variations in, Part I of tile Poisons Schedule In Part I of the Poisons Schedule- (a) in the item beginning with the words "Anti-histamin~ substances"'the words "(p-Ch1oraphenylpyrid-2-ylmethyl)2-dim~thylaminoethyl ether" shall be omitted, and after the word "Buc1izine" there shall be inserted the word "Carbinox;tmine" (being a different name for the same substance), and after the word "Thenali4ine" there shall be inserted the word "Tolpropamine"; (b) the words "Carbethoxysyringoy1methylreserpate; its salts" Shall be omitted, and after the, item beginning with the word ",Suprarenal" there shall be inserted the item "Syrosingopine" (being a different. name for the same substance); (c) after the item "Dyflas" -there shall be inserted the item !'Ecothiopate iodide"; (d) after the item "Etoxeridine; its salts" there shall be inserted the item "Fencamfamin; its salts"; , (e) the item "Hydrofluoric acid" shall be omitted; (f) after the item beginning wi~h the words "Mercury; oxides of" there shall be inserted the item "Metaxalone"; ,', (g) after the -item "Methoxsalen" there shall be inserted the item "a-Methyl" benzylhydrazine"; - - , (h) for the item "M.ustine; its,salt'$" there shall be substituted'the item "Mustine and ;tny other N-substituted derivative of 4i-(2-chloroethyl)amine' their salts"; an.d a~cordin~!y th:, it~ms . "C~orambucil; ,its salts;'., . '!Cyc1o­ phosphamlde; Its salts and. TnmustiIie; Its salts" (bemg. such derivatives and salts as aforesaid) shall be omitted; . (a) S.R, & O. (N.I.) 1963 1 No, 197, 132 Poisons No. 34 (z) after the item "Nalorphine; its salils" there shall be inserted the item "Nicocodine; its salts"; (j) after the item beginning with the word "m-Nitrophenol" there sball be inserted the item "Noracymethadol; its salts"; (k) after the item "Tretamine; its salts" there sham be inserted the item "TFi-(l-aziridinyl)-l ; 4-benzoquinone"; (l) after the item "Tribromethyl alcohol" there shall be inserted the 1tem "Triclofos; its salts". SECOND SCHEDULE The P9i~ons Schedule PART I Acetanilide; alkyl acetanilides Acetylcarbromal Acetyldihydrocodei~e; its salts Alkali fluorides other than those specified in Part II of this S6hedule Alkaloids, the following; their salts, simple or complex; their quaternary compounds; :.- Aconite, alkaloids of Atropine Belladonna, alkaloidS of Brucine . Calabar bean, alkaloids of Coca, alkaloids of Cocaine Codeine Colchicum, alkaloi4s of Coniine Cotarnine Curare, alkaloids of; .curare bases Ecgonine; its esters Emetine Ephedra, alkaloids of Ergot, alkaloids of Gelsemium, .alkaloids of Homatropine Hyoscine Hyoscyamine Jaborandi, alkaloids of Lobelia, alkaloids of Morphine Papaverine Pomegranate, alkaloi<!s of Quebracho, alkaloids of, other than the alkaloids of red qUebracho Rauwolfia, alkaloids of; their derivatives; their salts . Sabadilla, alkaloids of . Solanaceous alkaloids not otherwise jncluded in this Schedule Stavesacre, alkaloids or . .... '. Strychnine Thebaine Veratrum, alkaloids of Yohimba, alkaloids of No. 34 Poisons 133 Allylisopropylacetylurea Allylptodine; its salts Alphameprodine; its salts Alphaprodine; its salts Amidopyriile; its salts; amidopyrine sulphonates; their salts Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic add or the derivatives Of these acids; their salts p-Aminoben~enesulphonamide; its salts; . derivatives of p-aminobenzenesulphon­ amide having any of the hydrogen atoms of the p-amino group or of the sulphonamide group substituted by another. radical; their salts p-Amino-benzoic acid, esters of; their salts B-Aminopropylbenzene; its salts; its N-alkyl derivatives; their salts; {3-amino- isopropyl benzene; its salts; its N-alkyl deriv3itives; their salts Amitriptyline Amyl nitrite Androgenic, oestrogenic and progestational substances, the following:­ Benzoestrol Derivatives of stilbene, dibenzyl or naphthalene with oestrogenic activity; their esters Steroid compounds with androgenic or oestrogenic or progestational activity; their esters . Anileridine; its salts Anti-histamine substances, the following; their salts; their molecular compounds : ~ Antazoline Bromodiphenhydramine Buclizine . Carbinoxamine Chlorocyclizine Chlorpheniramine Cinnarizine Clemizole Cyclizine Cyproheptadine 3-Di-n-butylaminomethyl-4·5: 6-trihydroxyphthalide Diphenhydramine Diphenylpyraline Doxylamine Isothipendyl Mebhydrolin Meclozine Phenindamine Pheniramine Phenyltoloxamine Promethazine pyrrobutamine Thenalidine Tolpropamine Triprolidine Substances being tetra~substituted N-derivatives of ethylenediamine or propylenediamine Antimony:, chlorides ?f; except ant!monl' trkhlori~e: oxides of antimony; sulphides of antImony; antimonates; antrmomtes; orgamc compounds of antimony Apiol and oil of parsley Apomorphine; its salts 134 Poisons NO'. 34 Arsenical substances, the following, except those specified in Part II of ,this Schedule: halides of arsenic; oxides of arsenic; arsenates; arsenitesi OJ;:ganic compounds of arsenic Azacyclonol; its salts Barbituric acid; its salts; derivatives of barbituric acid; their salts; compounds of barbituric acid, its salts,jts derivatives, their salts, with any other substance Barium, salts of, other than barium sulphate and the salts of barium specified in Part II of this Schedule Benactyzine; its salts Benze~hidine; its salts Benzoylmorphine; its salts BenZitropine; its salts Benzylmorphine; its salts Betamepr04ine; jts salts Betaprodine; its salts Bromvaletone Busulphan; its saLts Butylchloral hydrate Cannabis (the dried flowering or fru1ting tops of Cannabis sativa. Linn.); the resin of cannabis; extracts of cannabis; tinctures of cannabis; cannabin tannate Cantharidin; cantharidates Captodiame; its salts Carbachol Carbromal Carisoprodol Chloral formamide Chloral hydrate Chlordiazepoxide; its salts Chloroform 2-p-Chlorophenyl-3-methylbutahe-2: 3-diol Chlorothi.azi?e .and other derivatives of benzo-l: 2: 4-thhldiazine-7-sulphonamide
Load more

Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan
    Volume 3 | Number 3 Article 87 2012 Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan Albert I. Wertheimer Follow this and additional works at: http://pubs.lib.umn.edu/innovations Recommended Citation Ninan B, Wertheimer AI. Withdrawing Drugs in the U.S. Versus Other Countries. Inov Pharm. 2012;3(3): Article 87. http://pubs.lib.umn.edu/innovations/vol3/iss3/6 INNOVATIONS in pharmacy is published by the University of Minnesota Libraries Publishing. Commentary POLICY Withdrawing Drugs in the U.S. Versus Other Countries Benson Ninan, Pharm.D.1 and Albert I Wertheimer, PhD, MBA2 1Pharmacy Intern, Rite Aid Pharmacies, Philadelphia, PA and 2Temple University School of Pharmacy, Philadelphia PA Key Words: Drug withdrawals, dangerous drugs, UN Banned Drug list Abstract Since 1979, the United Nations has maintained a list of drugs banned from sale in member countries. Interestingly, there are a number of pharmaceuticals on the market in the USA that have been banned elsewhere and similarly, there are some drug products that have been banned in the United States, but remain on the market in other countries. This report provides a look into the policies for banning drug sales internationally and the role of the United Nations in maintaining the master list for companies and countries to use for local decision guidance. Background recently updated issue is the fourteenth issue, which contains At present, one of the leading causes of death in the U.S. is data on 66 new products with updated/new information on believed to be adverse drug reactions.1-14 More than 20 22 existing products.
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Family Medicine (Fm-1) Multiple Choice Questions / Type I
    FAMILY MEDICINE (FM-1) MULTIPLE CHOICE QUESTIONS / TYPE I Select the correct answers to the following questions!!! ...each question may have more than one correct answer. FM-1.1. (g) Multiple Choice Question Renal calcification is a possible complication of: A) medullary cystic kidney disease B) renal tuberculosis C) sarcoidosis D) sickle cell anemia E) secondary hyperparathyroidism FM-1.2. Multiple Choice Question CV, IM Which of the following statements concerning chromosomes are correct? A) their number is normally 46 B) mosaicism is the coexistence of cells with different number of chromosomes within the same organism C) they are always identical in cells of the same phenotype D) nondisjunction must be followed by translocation E) they can be used as tumor markers FM-1.3. Multiple Choice Question IM Drugs with a bacteriostatic effect in regular doses include: A) tetracyclines B) cephalosporins C) sulfamethoxazole and trimethoprim (Sumetrolim) D) erythromycin E) amoxycillin FM-1.4. (a Multiple Choice Question Factors causing a susceptibility to urinary tract infect include: A) urinary tract obstruction B) diabetes mellitus C) hyperkalemia D) prolonged tetracycline therapy E) pregnancy 2 Multiple Choice Questions / Type I • FAMILY MEDICINE (FM-1) FM-1.5. Multiple Choice Question ~&, IM Case Study: The medical history of a 45-year-old male reveals episodes of vertigo and loss of consciousness associated with sweating. Possible causes of his symptoms include: A) hyperventilation B) hyperglycemia C) Zollinger-Ellison syndrome D) pheochromocytoma E) paroxysmal tachycardia FM-1.6. Multiple Choice Question IM Possible causes of hematemesis include: A) salicylate administration B) an oral iron supplement overdose C) severe burn injury D) Menetrier's disease (giant hypertrophic gastritis) E) feeding via a nasogastric tube FM-1.7.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios Et Al
    US 20060078604A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0078604 A1 Kanios et al. (43) Pub. Date: Apr. 13, 2006 (54) TRANSDERMAL DRUG DELIVERY DEVICE Related U.S. Application Data INCLUDING AN OCCLUSIVE BACKING (60) Provisional application No. 60/616,861, filed on Oct. 8, 2004. (75) Inventors: David Kanios, Miami, FL (US); Juan A. Mantelle, Miami, FL (US); Viet Publication Classification Nguyen, Miami, FL (US) (51) Int. Cl. Correspondence Address: A 6LX 9/70 (2006.01) DCKSTEIN SHAPRO MORN & OSHINSKY (52) U.S. Cl. .............................................................. 424/449 LLP (57) ABSTRACT 2101 L Street, NW Washington, DC 20037 (US) A transdermal drug delivery system for the topical applica tion of one or more active agents contained in one or more (73) Assignee: Noven Pharmaceuticals, Inc. polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can (21) Appl. No.: 11/245,180 control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmis (22) Filed: Oct. 7, 2005 sion rate of the polymeric backing layer. Patent Application Publication Apr. 13, 2006 Sheet 1 of 2 US 2006/0078604 A1 Fis ZZZZZZZZZZZZZZZZZZZ :::::::::::::::::::::::::::::::: Patent Application Publication Apr. 13, 2006 Sheet 2 of 2 US 2006/0078604 A1 3. s s 3. a 3 : 8 g US 2006/0078604 A1 Apr. 13, 2006 TRANSIDERMAL DRUG DELVERY DEVICE 0008. In the “classic' reservoir-type device, the active INCLUDING AN OCCLUSIVE BACKING agent is typically dissolved or dispersed in a carrier to yield a non-finite carrier form, Such as, for example, a fluid or gel.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]